Documentation scienceplus.abes.fr version Bêta

À propos de : Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis        

AttributsValeurs
type
Is Part Of
Subject
Title
  • Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis
has manifestation of work
related by
Abstract
  • BACKGROUND. Controlling lung inflammation may be the key to improving morbidity and mortality in cystic fibrosis. OBJECTIVE. To assess the effects of inhaled corticosteroids on lung inflammation in cystic fibrosis. DESIGN. Double blind placebo controlled randomised sequence crossover trial. Fluticasone propionate (400 μg/day) was given as a dry powder inhaler for six weeks with a four week washout period before crossover. OUTCOME MEASURES. Sputum inflammatory markers (interleukin-8, tumour necrosis factor-α (TNF-α) and neutrophil elastase—both free and bound to α1-antiprotease), sputum interleukin-10, lung function, and symptomatology. SUBJECTS. Twenty three children from a regional cystic fibrosis centre were enrolled into the study, with mean age 10.3 years (range 7 to 17 years) and mean baseline forced expiratory volume in one second (FEV1) of 64% (range 21% to 102%) predicted for sex and height. One patient was excluded for non-compliance to the study protocol. RESULTS. No significant benefit was shown for the use of fluticasone propionate in any of the outcomes. For sputum interleukin-8 there was an estimated true treatment median difference of 142 pg/ml (95% confidence interval (CI) 8 to 2866 pg/ml) in favour of placebo; while for maximal expiratory flow at 25% (MEF25%) remaining forced vital capacity predicted for sex and height there was a 15 percentage points (pp) (95% CI 4 to 26 pp) mean treatment difference in favour of placebo. Sputum interleukin-10 was undetected in any samples and unaffected by fluticasone propionate. Neither atopic status, baseline FEV1, nor concomitant DNase therapy had any effect on response to treatment. CONCLUSIONS. Lack of benefit from fluticasone propionate was most likely due to failure of the drug to penetrate the viscid mucus lining the airways. It is suggested a large multicentre trial with higher doses given for a longer time by a different delivery system is required to assess efficacy.
article type
publisher identifier
  • 96794
is part of this journal
PubMed ID
  • 9301350



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata